Abstract: An automated bioreactor system for decellularizing an organ includes a main chamber for containing the organ. The system further includes a reagent chamber containing a liquid phase reagent. A reagent conduit delivers the liquid phase reagent to the main chamber, and a perfusion conduit delivers the reagent from the reagent outlet in the main chamber into the organ. A perfusion pump drives the flow of the reagent. A perfusion pressure sensor detects a pressure of the flowing reagent. A control system controls the perfusion pump to drive the flow of the reagent based on a received input representative of a desired pressure and a received input of the detected pressure. The control system may automatically perform all of the steps of a decellularization protocol based on sensor input. An automated waste decontamination system may also be provided.

Abstract: A clot removal system comprises a catheter, a vacuum source, and a controller. The catheter comprises a proximal end, a distal end, and controller operating parameters and defines a lumen configured to be filled with a liquid column having a proximal portion. The vacuum source is configured to supply vacuum. The controller is configured to carry out a control pattern of turning on and off the vacuum based upon the controller operating parameters and is configured to receive the controller operating parameters in an automatic response to the catheter being operatively connected to at least one of the vacuum source and the controller and, responsive to the connection, to carry out the control pattern to change a level of vacuum at the distal end of the catheter.

Abstract: A clot removal system comprises a catheter, a vacuum source, and a controller. The catheter comprises a proximal end, a distal end, and controller operating parameters and defines a lumen configured to be filled with a liquid column having a proximal portion. The vacuum source is configured to supply vacuum. The controller is configured to carry out a control pattern of turning on and off the vacuum based upon the controller operating parameters and is configured to receive the controller operating parameters in an automatic response to the catheter being operatively connected to at least one of the vacuum source and the controller and, responsive to the connection, to carry out the control pattern to change a level of vacuum at the distal end of the catheter.

Abstract: Methods, systems and apparatuses may provide for technology that determines measured timing data in response to a presentation request from an application, wherein the measured timing data is associated with one or more previous frames and the presentation request is associated with one or more subsequent frames. The technology may also determine scheduling times for the subsequent frame(s) based on the measured timing data, wherein the scheduling times include a simulation time, a rendering time, a driver submission time, a hardware submission time, and a display time. In one example, the technology controls a pacing of the subsequent frame(s) on a display in accordance with the scheduling times.

Abstract: An aspiration thrombectomy system includes a thrombectomy catheter assembly that maintains pulsatile energy of cyclic aspiration while the catheter is occluded. A system configuration includes a catheter, vacuum and vent fluid sources respectively connected to vacuum and vent valves, a vent catheter valve connecting a catheter lumen to the vent fluid source, a manifold connected to the catheter and vacuum and vent valves, a pressure sensor upstream of the vacuum valve, and a controller configured to operate the vacuum, vent, and vent catheter valves, receive sensor pressure data, control the vent catheter valve dependent upon the data. Determination can be upon decrease of pressure waveform amplitude. An operable lumen of the system includes a volume of the catheter lumen and an interior of the manifold up to an input of the vacuum valve input and an output of the vent valve.

Abstract: An automated bioreactor system for decellularizing an organ includes a main chamber for containing the organ. The system further includes a reagent chamber containing a liquid phase reagent. A reagent conduit delivers the liquid phase reagent to the main chamber, and a perfusion conduit delivers the reagent from the reagent outlet in the main chamber into the organ. A perfusion pump drives the flow of the reagent. A perfusion pressure sensor detects a pressure of the flowing reagent. A control system controls the perfusion pump to drive the flow of the reagent based on a received input representative of a desired pressure and a received input of the detected pressure. The control system may automatically perform all of the steps of a decellularization protocol based on sensor input. An automated waste decontamination system may also be provided.

Abstract: The current application is directed to a method for treating pulmonary arterial hypertension (PAH), comprising: providing isolated endothelial progenitor cells (EPCs); treating the EPCs with prostacyclin, wherein the treated EPCs exhibit a hyperproliferative phenotype with enhanced angiogenic property; and administering a composition comprising the treated EPCs into a subject suffering from PAH.

Abstract: Provided are methods for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided.

Abstract: A method automatically detects stability of a regulator cascade having a number of cascaded regulators. A regulation error of a respective regulator is processed by the respective regulator and the processed regulation error is output as a regulator manipulated variable. A reference variable for the respectively downstream regulator in the regulator cascade is ascertained as a function of the regulator manipulated variable. The method includes: ascertaining an energy content of a respective regulation error; ascertaining whether an absolute value of a respective regulator manipulated variable exceeds an associated limiting value or not; and generating a stability measure for the regulator cascade as a function of the energy contents of the respective regulation errors and as a function of whether the respective regulator manipulated variables exceed their associated limiting values or not.

Abstract: The current application is directed to a method for treating pulmonary arterial hypertension (PAH), comprising: providing isolated endothelial progenitor cells (EPCs); treating the EPCs with prostacyclin, wherein the treated EPCs exhibit a hyperproliferative phenotype with enhanced angiogenic property; and administering a composition comprising the treated EPCs into a subject suffering from PAH.

Abstract: Provided are methods for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided.

Abstract: A method of attenuating annular pressure buildup within a wellbore. The method includes accessing a wellbore, with the wellbore having an annulus disposed between first and second strings of casing. The method also includes placing a column of cement around the second string of casing generally below the first string of casing. The method further includes pumping a fluid mixture into the annulus, forming a fluid column. The fluid mixture comprises a carrier fluid, and a plurality of compressible particles dispersed in the carrier fluid. Each of the compressible particles is fabricated to partially collapse in response to thermal expansion of the fluid mixture. The method also includes placing a wellhead over the wellbore, thereby forming a trapped annulus in the wellbore. The method additionally includes at least partially sealing the annular region along at least one depth above the column of cement to inhibit vertical migration of the compressible particles.

Abstract: The present invention relates to compositions comprising a decellularized tissue. The present invention also provides an engineered three dimensional lung tissue exhibiting characteristics of a natural lung tissue. The engineered tissue is useful for the study of lung developmental biology and pathology as well as drug discovery.

Abstract: A method of attenuating annular pressure buildup within a wellbore. The method includes running first and second strings of casing into a wellbore, wherein the first string of casing surrounds an upper portion of the second string of casing forming an annular region. The method also includes providing a packing of compressible material within the annular region. The compressible material comprises carbonaceous particles. The particles may reside within a porous sleeve or filter, or they may be packed together in a matrix using a cross-linked polymer or binder. The packing is fixed at a selected depth within the annular region, and is designed so that the compressible material absorbs pressure in response to thermal expansion of wellbore fluids during the production of hydrocarbon fluids from the wellbore. The method further includes placing a wellhead over the wellbore, thereby forming a trapped annulus in the wellbore over the annular region.

Abstract: Described herein are methods and compositions for use in improving a vascular barrier of endothelial cells. The methods may include the use of barrier agonist compounds and improved techniques for culturing endothelial cells. The improved methods and compositions for culturing endothelial cells may include at least one or more of the following: an adenylyl cyclase activator; an activator of Sphingosine-1-phosphate (S1P) receptor internalization; a direct or indirect inducer of tight junction protein expression, and a direct or indirect inducer of adherens junction protein expression.

Abstract: The application is directed to a method for treating or preventing vasculopathy comprising administrating to a subject in need thereof a pharmaceutical composition comprising mesenchymal precursor cells (MPCs) and a prostacyclin. Also provided a method for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided.

Abstract: The present invention relates to compositions comprising a decellularized tissue. The present invention also provides an engineered three dimensional lung tissue exhibiting characteristics of a natural lung tissue. The engineered tissue is useful for the study of lung developmental biology and pathology as well as drug discovery.

Abstract: A collection of compressible particles. The compressible particles are intended to be used for attenuating pressure build-up within a confined volume such as a trapped annulus in a wellbore. Each of the compressible particles is fabricated to collapse in response to fluid pressure within the confined volume, and comprises carbon. Particularly, each of the particles comprises a plurality of peripheral openings, permitting an ingress of wellbore fluids in response to an increase in pressure within a trapped annulus. The collection of compressible particles together has a reversible volumetric expansion/contraction of ?10% and up to 25% at pressures up to 10,000 psi. A method of attenuating annular pressure buildup within a wellbore using the collection of compressible particles is also provided.

Abstract: Systems and methods are provided for evaluating a tissue that utilize a resistance to represent pressure of a fluid or gas passing through the tissue and a capacitance to represent compliance of the tissue.

Abstract: Methods, systems and apparatuses may provide for technology that determines measured timing data in response to a presentation request from an application, wherein the measured timing data is associated with one or more previous frames and the presentation request is associated with one or more subsequent frames. The technology may also determine scheduling times for the subsequent frame(s) based on the measured timing data, wherein the scheduling times include a simulation time, a rendering time, a driver submission time, a hardware submission time, and a display time. In one example, the technology controls a pacing of the subsequent frame(s) on a display in accordance with the scheduling times.